We are pleased to announce our successful DCP submission for Riociguat tablets.
Based on the reference brand, Adempas, Riociguat is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with inoperable Chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. The product is also indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH)
The brand sold approximately $323 Million globally in 2022, having a significant growth potential with Global 3Y CAGR at +6%, according to IQVIA.
In addition to this achievement, we are excited to highlight Adalvo's commitment to advancing cardiovascular care. Our comprehensive portfolio encompasses a range of cardiovascular dossiers, including Riociguat tablets. These dossiers exemplify our dedication to improving the well-being of patients dealing with various cardiovascular conditions. Our cardiovascular dossiers include, but are not limited to:
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!